PRME Stock Analysis: Buy, Sell, or Hold?
PRME - Prime Medicine, Inc. Common Stock
$3.24
-0.13 (-3.86%)
▼
5d:
+11.72%
30d:
+9.83%
90d:
-9.5%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When PRME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PRME shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PRME shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PRME is currently trading at $3.24, which is considered slightly high relative to its 30-day fair value range of $2.82 to $3.31.
Technical Outlook: Technically, PRME is in a strong uptrend. Immediate support is located at $2.67, while resistance sits at $3.57. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: PRME has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.92 (+113.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRME is in a strong uptrend. Immediate support is located at $2.67, while resistance sits at $3.57. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: PRME has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.92 (+113.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.82 -
$3.31
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 113.5% below Wall St target ($6.92)
Trading Range Analysis
30-Day Trading Range
$2.82 -
$3.31
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.67
Resistance Level
$3.57
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.72
Wall Street Target
$6.92
(+113.5%)
Revenue Growth (YoY)
-41.1%
Share & Embed Analysis
Last updated: June 24, 2026 4:25 AM ET
Data refreshes hourly during market hours. Next update: 5:25 AM
Data refreshes hourly during market hours. Next update: 5:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
Advanced PRME Option Strategies
Professional options setups generated by AI based on today's PRME price and gamma walls.
